Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by HC Wainwright

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com upgraded Lexicon Pharmaceuticals to a “sell” rating in a report on Tuesday, July 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $7.50.

Lexicon Pharmaceuticals Stock Up 3.9 %

LXRX stock opened at $1.60 on Friday. The company has a 50 day moving average of $1.77 and a two-hundred day moving average of $1.84. The company has a market cap of $393.98 million, a price-to-earnings ratio of -1.93 and a beta of 1.33. Lexicon Pharmaceuticals has a 12-month low of $0.92 and a 12-month high of $3.73. The company has a quick ratio of 11.49, a current ratio of 11.51 and a debt-to-equity ratio of 0.41.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative return on equity of 105.38% and a negative net margin of 5,509.34%. The business had revenue of $1.65 million during the quarter, compared to analyst estimates of $2.74 million. During the same period last year, the company earned ($0.22) earnings per share. On average, equities analysts anticipate that Lexicon Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Large investors have recently bought and sold shares of the business. Cantor Fitzgerald L. P. bought a new position in Lexicon Pharmaceuticals during the fourth quarter valued at about $25,000. CVI Holdings LLC bought a new stake in Lexicon Pharmaceuticals during the second quarter worth approximately $34,000. Principal Financial Group Inc. boosted its position in Lexicon Pharmaceuticals by 116.1% during the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 12,225 shares during the period. Great Point Partners LLC acquired a new position in Lexicon Pharmaceuticals during the second quarter valued at approximately $50,000. Finally, Virtu Financial LLC bought a new position in shares of Lexicon Pharmaceuticals in the first quarter valued at approximately $105,000. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.